Polarean, Inc.

03/26/2026

We’re excited to share highlights from a recent milestone event in Taiwan! 🇹🇼

A big thank you to Professor Yuh-Chin Tony Huang (Duke Health) for leading an engaging session with the Departments of Pulmonology and Radiology at National Taiwan University Hospital (NTUH), helping build momentum for at Polarean’s first site in the APAC region.

The discussion explored the growing role of noninvasive, radiation-free functional lung imaging in diseases such as COPD and interstitial lung diseases (ILDs). With the ability to visualize regional lung function in a short breath-hold acquisition, Xenon MRI may offer additional insight into disease heterogeneity patterns and support longitudinal monitoring over time.

We’re also grateful to Sumtage, our distribution partner in Taiwan, for bringing together leading clinicians and researchers for this important exchange.

This marks an important step forward as we continue expanding access to advanced lung imaging globally.

Learn more: xenoview.net

03/24/2026

At LSI - Life Science Intelligence (LSI) USA ’26 in Dana Point, Polarean CEO Christopher von Jako, PhD took the stage to discuss the expanding role of advanced functional imaging in cardiopulmonary disease.

With more than 2,000 attendees, the momentum was clear: technologies that deliver earlier, more precise insight into lung function are becoming increasingly important for improving diagnosis and accelerating therapeutic development.

At Polarean, we’re advancing to help make cardiopulmonary disease more visible and actionable across both research and clinical care.

Thank you to the LSI team for bringing together such a dynamic and forward-looking community!

03/11/2026

For millions of people living with chronic lung disease, including COPD, interstitial lung diseases (ILDs), and severe asthma, pulmonary rehabilitation can help restore strength, endurance, and confidence in daily life.

Yet despite these benefits, pulmonary rehabilitation remains underutilized and underrecognized.

Greater insight into lung function may also help support rehabilitation programs. Tools that visualize regional lung function can provide clinicians with additional perspective and help patients better understand how their lungs are responding to care—supporting engagement and shared decision-making over time.

During (March 8–14), we recognize the respiratory therapists, pulmonologists, rehabilitation specialists, and advocates working every day to expand access to pulmonary rehab and improve outcomes for people living with lung disease.



AACVPR Lung Health Foundation American Lung Association
American Association for Respiratory Care - AARC
Pulmonary Fibrosis Foundation European Pulmonary Fibrosis Federation American College of Chest Physicians

03/03/2026

At last week’s Society of Thoracic Radiology ( ) Annual Meeting in Puerto Rico, functional lung imaging was a central theme in conversations about pulmonary disease.

From well-attended sessions to thoughtful discussions in the exhibit hall, it was clear that interest in regional functional imaging continues to grow across thoracic oncology, interstitial lung disease, pulmonary vascular disease, and surgical planning.

A highlight of the meeting was the session on clinical implementation, where Alan Ropp, MD, MS from UVA Health shared real-world experience integrating functional lung MRI into practice.

We appreciated the candid dialogue from radiologists around workflow, adoption, and where functional imaging delivers meaningful clinical value.

Thank you to everyone who connected with our team. We’re energized by the collaboration and encouraged by the continued momentum around functional lung MRI in both research and clinical care.

If you’d like to continue the conversation or learn more, connect with us here:
👉 https://xenoview.net/customer-support/

02/27/2026

300 million people worldwide are living with rare diseases. Many of these conditions affect the lungs and the ability to breathe, impacting both children and adults.

For patients and families, the journey often includes long diagnostic paths, uncertainty, and the need for ongoing monitoring. More sensitive ways to understand lung function earlier in disease progression can play an important role in supporting care over time.

Some people living with rare lung and cardiopulmonary conditions may struggle to perform spirometry consistently. If you’re interested in learning more about a low-effort lung function assessment that can be completed in a single 10–15 second breath-hold, we welcome you to connect with us.

On Rare Disease Day, we stand with patients, families, clinicians, and researchers working to advance understanding, improve monitoring, and move toward better outcomes for rare lung disease.

Learn more: https://www.rarediseaseday.org/

02/19/2026

We’re excited to share that our CEO, Christopher von Jako, PhD, will be presenting at !

LSI USA brings together healthcare leaders, innovators, and investors to explore what’s next in medtech. We look forward to sharing how Polarean’s platform is advancing functional lung imaging and helping deliver new insights into pulmonary health.

If you’ll be attending LSI USA ’26, we’d love to connect.

Want to learn more or get in touch with our team?
👉 https://xenoview.net/customer-support/

02/12/2026

Did you catch Polarean’s platform featured in the January/February issue of Radiology Today Magazine?

In the article, our CEO Christopher von Jako, PhD, shares how Xenon MRI is advancing functional lung imaging by capturing ventilation images in 10 seconds or less ⏱️ and delivering regional functional insight that conventional imaging and spirometry often can’t provide.

“We’re imaging the gas, not the water content or tissue signal in the lung. If there’s any place where the xenon can’t get to, oxygen is not getting there either,” Chris explains.

This noninvasive, radiation-free technology is opening new doors for visualizing lung function and is being explored across clinical and research settings for conditions including asthma, COPD, cystic fibrosis, and unexplained breathlessness, in adults and children as young as 6. 🫁

👉 Read the full article:
https://www.radiologytoday.net/archive/rt_JF26p6.shtml

Radiology Today newsmagazine reaches 40,000 radiology professionals nationwide on a monthly basis, covering areas such as Radiology Management, Bone Densitometry, Mammography, MRI, PACS, CT, Sonography, Nuclear Medicine, Radiation Oncology, Radiation Therapy, contrast agents, and more!

02/10/2026

We’re excited to be exhibiting at the Society of Thoracic Radiology ( ) Annual Meeting this February 21–25 in Puerto Rico!

STR 2026 features a robust agenda spanning thoracic oncology, interstitial lung disease, cardiopulmonary imaging, AI, and emerging MRI techniques, including a dedicated session on and clinical implementation with Alan Ropp, MD, MS from UVA Health.

If you’ll be attending STR, stop by our exhibit and connect with the team:

🔹 Alan Huang, Vice President Sales
🔹 Daniel Booker, Central Sales Director
🔹 J. Fernando Corredor, Western Sales Director

We’d love to discuss how functional lung MRI is being integrated into clinical practice and research.

Want to connect with our team or learn more about Xenon MRI? Reach out here:
👉 https://xenoview.net/customer-support/

02/04/2026

We had a great time connecting with the community at the 11th Annual Xenon MRI Clinical Trials Consortium (XeCTC) Meeting last week, where clinicians, researchers, and industry partners came together to share advances in functional lung imaging and clinical implementation.

As lead sponsor, Polarean was proud to support a dynamic agenda focused on:

✔️ Emerging clinical applications of Xenon MRI across pulmonary and cardiopulmonary disease
✔️ Real-world implementation and workflow considerations
✔️ New research exploring functional imaging biomarkers
✔️ Collaboration to advance adoption and evidence generation

Thank you to for all the presenters and attendees for the engaging discussions and shared commitment to improving lung health through innovation.

We’re excited to continue working with the XeCTC community to help move functional lung MRI forward in both research and clinical practice.

Want to learn more about Xenon MRI? Connect with us here:
👉 https://xenoview.net/customer-support/

02/03/2026

February is American Heart Month ❤️

The heart and lungs function as a closely connected system. Growing research shows that changes in lung function can reflect cardiovascular stress and risk, highlighting the importance of understanding cardiopulmonary health together, not in isolation.

At Polarean, our platform delivers detailed, noninvasive, radiation-free insight into lung function, offering a new way to visualize and better understand diseases that impact both the heart and lungs.

This Heart Month, we’re celebrating innovation that supports a more connected, patient-centered view of cardiopulmonary health.

🌟 Explore the heart–lung connection and ways to protect both: https://www.lung.org/blog/heart-lung-relationship

🌟 Want to learn more about Xenon MRI or connect with our team? Reach out here: https://xenoview.net/customer-support/



American Heart Association

01/29/2026

Pulmonary hypertension ( ) is a serious, life-threatening disease that puts extreme strain on the heart and lungs. The diagnosis and follow-up of patients with PH is challenging due to the absence of clear biomarkers that reflect the complexity of its underlying pathophysiology.

New research from Duke University by Fawaz Alenezi, Anna Costelle, Seth Lee, Bastiaan Driehuys, and Sudarshan Rajagopal is exploring investigational uses of Xenon MRI to study gas exchange and lung microvascular function in PH. This area of active research may deepen understanding of this complex disease and support the development of quantitative imaging biomarkers.

The authors describe how may:

✔️ Reveal regional functional abnormalities not seen with conventional imaging
✔️ Provide insight into different PH subtypes through gas exchange metrics
✔️ Capture early physiologic changes in the disease and treatment response

📖 Read the study: https://pubmed.ncbi.nlm.nih.gov/40600715/

01/20/2026

📣 Polarean Expands Xenon MRI into Cardiopulmonary Drug Development

Polarean has reached an important milestone by expanding the platform into pharma-sponsored cardiopulmonary drug development through a multi-center U.S. study in pulmonary hypertension associated with interstitial lung disease (PH-ILD).

In collaboration with a leading cardiopulmonary pharmaceutical company and VIDA, this work leverages quantitative Xenon MRI biomarkers to directly measure treatment effects at the pulmonary capillary level, an area of lung physiology that has historically been difficult to assess with conventional tools.

🔬 Xenon MRI has the potential to support:

❇️ Early pharmacodynamic readouts in clinical studies
❇️ Differentiation between inhaled and systemic therapies based on mechanism of action
❇️ Improved patient characterization as predominantly left-heart disease (post-capillary) or right-heart disease (pre-capillary)
❇️ Greater endpoint sensitivity in cardiopulmonary clinical trials

By pairing an inhaled therapy with an inhaled imaging signal, Xenon MRI delivers a noninvasive, radiation-free approach to quantify regional functional changes in lung ventilation, gas diffusion across the interstitial membrane, pulmonary capillary blood volume, and microvascular hemodynamics, all within a short breath hold.

This expansion highlights Xenon MRI’s growing role as a powerful imaging biomarker platform for cardiopulmonary drug development, supporting precise evaluation of therapies in diseases with high unmet need.

Read the full announcement:https://polarean.com/wp-content/uploads/2026/01/Polarean-Expands-Xenon-MRI-Platform-into-Cardiopulmonary-Drug-Development_2026-01-20.pdf

Arun Jose, MD, MS, University of Cincinnati, Sudar Rajagopal, MD, PhD, Duke University, Leslie Spikes, University of Kansas Medical Center